GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...

Weight-loss drugs like Ozempic have rapidly switched from diabetes therapy to mass-market weight control, shrinking appetites ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

HOUSTON, TEXAS / ACCESS Newswire / July 1, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an ...

Geneva: The World Health Organization (WHO) has issued a global safety alert highlighting the risk of non-arteritic anterior ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...